NYSE · Drug Manufacturers - General

Zoetis Inc. (ZTS) Stock

$81.03 -1.18% NYSE: ZTS Healthcare

Valuation

MetricValue
Price$81.03
Market Cap$33.48B
P/E Ratio11.69
P/B Ratio9.43
P/S Ratio3.13
EPS (TTM)$6.02
52-Week High$148.79
52-Week Low$69.03
Dividend Yield2.98%

Financials & Margins

MetricValue
ROE69.25%
ROA17.35%
ROCE27.05%
Gross Margin38.00%
Operating Margin38.00%
Net Margin27.49%
Debt/Equity2.93
Current Ratio3.03

Annual Financials (USD)

Metric20212022202320242025
Revenue$7.8B$8.1B$8.5B$9.3B$9.5B
Operating Profit$2.8B$2.9B$3.1B$3.4B$3.6B
Net Profit$2.0B$2.1B$2.3B$2.5B$2.7B
EPS$4.27$4.49$5.07$5.47$6.02
Op Margin36.0%36.2%35.9%36.6%38.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$13.9B$14.9B$14.3B$14.2B$15.5B
Total Liabilities$9.4B$10.5B$9.3B$9.5B$12.1B
Cash$3.5B$3.6B$2.0B$2.0B$2.3B
Borrowings$6.7B$8.1B$6.8B$6.7B$9.5B

Latest News

Zoetis Launches Lenivia® (izenivetmab injection) in Canada and the European Union Business Wire · Jul 15, 2026 Zoetis (ZTS) Stock Dips While Market Gains: Key Facts Zacks · Jul 14, 2026 Zoetis to Acquire Veterinary Teleradiology Services Platform VitalRADS MT Newswires · Jul 14, 2026 Zoetis Announces Agreement to Acquire VitalRADS, Accelerating Diagnostic Capabilities Business Wire · Jul 14, 2026 Leerink Partners Adjusts Zoetis Price Target to $80 From $95, Maintains Market Perform Rating MT Newswires · Jul 13, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$2.2B$1.9B$2.4B$3.0B$2.9B
Investing Cash Flow$-935.0M$-1.5B$-1.5B$-970.0M$-1.4B
Financing Cash Flow$-788.0M$-1.6B$-1.1B$-1.9B$-3.2B
Net Cash Flow$-119.0M$96.0M$-1.5B$-54.0M$325.0M
Free Cash Flow$1.7B$1.3B$1.6B$2.3B$2.3B

Valuation & Return Ratios

MetricValue
PEG Ratio2.62
EV / EBITDA9.69
FCF Yield7.94%
Quick Ratio1.84
Interest Coverage14.43
Return 1Y-43.59%
Return 3Y-49.49%
Return 5Y-59.19%

Ownership

Insiders Held0.15%
Institutions Held102.86%
Institutions Float Held103.02%
Institutional HolderSharesReport Date
Blackrock Inc.35,584,3122026-03-31
Vanguard Capital Management LLC26,072,8462026-03-31
Vanguard Portfolio Management LLC23,967,4002026-03-31
State Street Corporation19,324,4012026-03-31
State Farm Mutual Automobile Insurance Co15,892,9032026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ELANElanco Animal Health Incorporated $22.52 -0.75% -54.00 $11.25B 0.00%
IDXXIDEXX Laboratories, Inc. $560.38 -1.13% 36.46 $44.15B 0.00%
MRKMerck & Company, Inc. Common Stock (new) $145.27 -1.34% 118.05 $358.41B 2.29%
NEOGNeogen Corporation $12.19 +1.75% -365.96 $2.66B 0.00%
PAHCPhibro Animal Health Corporation $38.80 -2.54% 15.14 $1.58B 1.29%

About Zoetis Inc.

Zoetis Inc. is led by CEO Kristin C. Peck, employs 13,800 people, headquartered in Parsippany, US, publicly traded since 2013.

Zoetis Inc. (ZTS) stock trades at $81.03 with a market capitalization of $33.48B. The stock is valued at a price-to-earnings (P/E) ratio of 11.69, price-to-book of 9.43, price-to-sales of 3.13. Over the past 52 weeks the stock has ranged between $69.03 and $148.79, and currently trades 45.5% below its 52-week high. It pays a dividend yielding 2.98%.

On profitability, Zoetis Inc. generates a return on equity (ROE) of 69.25%, above the typical market range of roughly 12-15%, return on capital employed of 27.05%, an operating margin of 38.00%, a net profit margin of 27.49%.

In its most recent fiscal year, Zoetis Inc. reported annual revenue of $9.5B, net profit of $2.7B. Over the last 5 fiscal years, revenue grew at an average annual rate of 7.2%, and net profit grew at an average annual rate of 10.3%. Over that span net profit grew faster than revenue, so net margin widened.

The balance sheet shows a debt-to-equity ratio of 2.93 (debt more than twice shareholders' equity), a current ratio of 3.03, total assets of $15.5B, $2.3B in cash and equivalents.

ZTS has an average daily trading volume of 5,659,786 shares, a beta of 0.73 (historically less volatile than the overall market).

Zoetis Inc. by the numbers, 2016–2025

Between 2016 and 2025 Zoetis Inc. reported revenue of $4.9B rising to $9.5B, a change of +93.7% across 10 years. Compounded, revenue has grown 7.2% a year over five years, 5.4% over three, 2.3% over the last twelve months. Net profit rose to $2.7B.

Operating margin went from 28.7% in 2016 to 38.0% in 2025, a gain of 9.3 percentage points. The most recent net margin is 27.49%. On a trailing twelve-month basis to Jun '26, revenue is $9.5B and net profit $2.6B.

Borrowings rose from $4.5B to $9.5B, cash from operations was $2.9B in the latest year, positive in 10 of the last 10.

Return on equity has averaged 54.4% over five years, and was 80.3% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Zoetis Inc. (ZTS) — frequently asked questions

What is Zoetis Inc. (ZTS) stock price today?

Zoetis Inc. (ZTS) is currently trading at $81.03, down 1.18% today.

What is ZTS P/E ratio?

Zoetis Inc.'s P/E ratio is 11.69. This is below the typical market average of roughly 18-22x. A low P/E can reflect a lower valuation, slower expected growth, or both.

What is ZTS return on equity (ROE)?

Zoetis Inc.'s return on equity (ROE) is 69.25%. ROE measures net income relative to shareholders' equity. This is above the typical market range of roughly 12-15%.

What is Zoetis Inc.'s market cap?

Zoetis Inc. has a market capitalization of $33.48B.

Does ZTS pay a dividend?

Yes. Zoetis Inc. currently yields 2.98%. Yield moves with the share price, so it changes daily even when the payment does not.

How much debt does ZTS carry?

Zoetis Inc. has a debt-to-equity ratio of 2.93. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is ZTS's profit margin?

Zoetis Inc. reports a net profit margin of 27.49% — the share of revenue left after every cost, including tax and interest.

What sector is ZTS in?

Zoetis Inc. is classified under Healthcare, in the Drug Manufacturers - General industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is ZTS listed on?

Zoetis Inc. trades on NYSE under the ticker ZTS.

What is ZTS's 52-week range?

Over the last year Zoetis Inc. has traded between $69.03 and $148.79.

Related Healthcare Stocks

LLY Eli Lilly and Company $1273.46 -2.54% JNJ Johnson & Johnson $263.81 -1.42% ABBV AbbVie Inc. $285.64 +0.16% UNH UnitedHealth Group Incorporated Common Stock (DE) $418.09 -1.62% MRK Merck & Company, Inc. Common Stock (new) $145.27 -1.34% NVS Novartis AG $151.12 -3.30% AZN AstraZeneca PLC $171.49 -0.63% TMO Thermo Fisher Scientific Inc $673.82 -0.40% AMGN Amgen Inc. $439.26 -1.79% GILD Gilead Sciences, Inc. $156.04 -0.73% ABT Abbott Laboratories $103.70 +1.16% NVO Novo Nordisk A/S $39.05 -0.96%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens ZTS currently matches

On the figures above, Zoetis Inc. passes the filters for 22 of our ready-made screens, among them Low PE Stocks, Undervalued Large Cap Stocks, Undervalued Dividend Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Low PE StocksUndervalued Large Cap StocksUndervalued Dividend StocksDividend StocksS&P 500 Dividend StocksHigh ROE StocksHigh Profit Margin StocksHigh ROA StocksCompanies With Highest ROELarge Cap StocksStocks With Insider BuyingHealthcare Stocks To BuyStock Screener StarterFree Stock Screener PicksStocks With PE Under 20Low PE High EPS StocksHigh ROCE StocksHigh Debt to Equity StocksStocks Under $100High ROCE Low PE StocksLow PE High ROE StocksLarge Cap Dividend Stocks

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNYSE High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.